MARKET

ACOR

ACOR

Acorda Thrpeutcs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4200
+0.0060
+1.45%
After Hours: 0.4200 0 0.00% 19:08 05/27 EDT
OPEN
0.4180
PREV CLOSE
0.4140
HIGH
0.4349
LOW
0.4100
VOLUME
629.99K
TURNOVER
0
52 WEEK HIGH
6.36
52 WEEK LOW
0.4010
MARKET CAP
5.58M
P/E (TTM)
-0.0506
1D
5D
1M
3M
1Y
5Y
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares rose 20.9% to $0.70 in pre-market trading after dropping 12% on Wednesday. Acorda Therapeutics recently posted a Q1 loss of $1.66 per share.
Benzinga · 05/19 10:44
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Acorda partners with Biopas to sell Parkinson's disease therapy in Latin America
The commercial-stage biotech, Acorda Therapeutics (NASDAQ:ACOR), and South American pharma company, Biopas Laboratories announced an agreement on Wednesday to commercialize Acorda’s (ACOR) Parkinson's disease therapy Inbrija in certain Latin American
Seekingalpha · 05/11 20:16
Acorda Therapeutics Reiterates Guidance
Financial Guidance For the full year 2022, Acorda continues to expect AMPYRA net revenue to be $68 – $78 million, and operating expenses to be $110 – $120 million. The
Benzinga · 05/11 20:04
Acorda Therapeutics Q1 EPS $(1.66) Up From $(2.46) YoY, Sales $22.53M Miss $36.97M Estimate
Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(1.66) per share. This is a 32.52 percent increase over losses of $(2.46) per share from the same period last year. The company reported quarterly sales of
Benzinga · 05/11 20:04
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
ARDSLEY, N.Y. & PANAMA CITY, May 11, 2022--Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
Business Wire · 05/11 20:01
-- Earnings Flash (ACOR) ACORDA THERAPEUTICS Posts Q1 Revenue $22.5M
MT Newswires · 05/11 16:04
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
More
No Data
Learn about the latest financial forecast of ACOR. Analyze the recent business situations of Acorda Thrpeutcs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACOR stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 0.4200
EPS
Actual
Estimate
-1.67-1.25-0.84-0.42
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q4 2021
Institutional Holdings
Institutions: 185
Institutional Holdings: 6.73M
% Owned: 50.66%
Shares Outstanding: 13.29M
TypeInstitutionsShares
Increased
12
570.52K
New
5
320.90K
Decreased
6
25.66K
Sold Out
7
102.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
John Kelley
Chief Executive Officer/President/Director
Ron Cohen
Chief Financial Officer
Michael Gesser
Chief Operating Officer
Lauren Sabella
General Counsel
Neil Belloff
Other
Kerry Clem
Independent Director
Peder Jensen
Independent Director
Sandra Panem
Independent Director
Lorin Randall
Independent Director
John Varian
No Data
No Data
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.